“Most charitable organisations and bodies still have to buy drugs
through distributors of pharma products and that is where the price
tends to go up,” adds the doctor who used to head the APAC project with
VHS and USAid. “The patients will also have certain expectations, which
we need to manage,” he explains.
So when a newer, more
expensive drug hits the market, the cheaper alternative begins arriving
‘late’ or is perennially unavailable or does not seem to be accessible
within reasonable means. “These are some of the tactics that pharma
companies use to ensure their drugs do well. We are also involved at
some level but that’s the cost of doing business,” points out an office
bearer of a medical representatives trade union.
With no
foreseeable option but to purchase and disburse the drug, hospitals
often resort to various strategies to try not to pass them on to
economically backward patients. Dr V Shanta, Chairperson of The Cancer
Institute, Adyar says that patented drug prices have always been a major
challenge to the institution from their early days. “Unacceptable high
prices are a burden to everyone and though a few pharmaceutical
companies come forward and give concessions and even a few drugs for
free, its been always a major challenge,” she said.
Dr Shanta
further observes that the institution has coped with the price increases
of drugs by following certain norms. “Our institution does not
prescribe unnecessary drugs to the patients. Careful use of drugs and
also use of drugs at the right time is what we follow. When we are sure
that the chemotherapy is not going to enhance the quality of life of the
patient, we do recommend palliative care, rather than putting them on
medicine. We also use generic medicine widely. We have been using
generic medicine from the early days. From experience, we have learned
that generic medicine is as effective as patented drugs. Patented drugs
are prescribed only for selective patients who insist on it. This is how
we manage with the price spike, she added.
Some hospitals have
deep purses, allowing them to absorb the drug cost, but that is
obviously not a solution. Dr J V Peter, Head of pharmacy Services,
Christian Medical College Hospital, Vellore said, every time there is an
increase of the price. It was they who bear the burden.
“We give
25 to 40 per cent discount to our patients. We don’t want to pass the
burden on them as we are rending service to the poor and needy. Price
increase affects all of us. Some companies come and offer discounts
understanding our service to the poor. They give us subsidy. But still,
not many do it. If it wasn’t for the philanthropists who help us, we
wouldn’t be able to do anything,” he remarks.
This state of
affairs exists despite the aggressive working of civil society in tandem
with the Chemicals and Fertiliser Ministry, which sets the
all-important Drug Prices Control Order, after the recommendations from
the National Pharmaceuticals Pricing Authority (NPPA). “Pharma companies
put a lot of pressure on these statutory bodies to ensure that their
drugs don’t get pushed on to the essential commodities list, because
then price caps will automatically come into place. If this happens,
then they push for flooding the market with the product to make up for
the margins lost,” says pharma activist and researcher J Surendran.
Is
there a way out? Generic drugs have been screaming for attention ever
since the centre announced the Jan Audhadhi programme in 2008 — to
distribute generic drugs to institutions and hospitals at a subsidised
rate, across the spectrum. With little manpower, resources or execution,
the project has been meandering till it picked up steam last year.
“Things
are gradually improving, which is one of the major reasons why we are
looking at signing an MoU with them — such that they can provide
quality, generic drugs to all our member hospitals that are involved in
charitable work. If this happens, it will be a vast and welcome change,”
says Dr Charles.
No comments:
Post a Comment